title: Is patient outcome compromised during the initial experience with robot-assisted radical cystectomy? Results of 164 consecutive cases.
abstract: OBJECTIVE
  • Robot-assisted radical cystectomy (RARC) remains controversial in terms of oncologic outcomes, especially during the initial experience. The purpose of this study was to evaluate the impact of initial experience of robotic cystectomy programs on oncologic outcomes and overall survival.
  
  
  METHODS
  • Utilizing a prospectively maintained, single institution robotic cystectomy database, we identified 164 consecutive patients who underwent RARC since November 2005. • After stratification by age group, gender, pathologic T stage, lymph node status, surgical margin status, and sequential case number; we used chi-squared analyses to correlate sequential case number to operative time, surgical blood loss, lymph node yield, and surgical margin status. • We also addressed the relationship between complications and sequential case number. We then utilized Cox proportional hazard modeling and Kaplan-Meier survival analyses to correlate variables to overall mortality.
  
  
  RESULTS
  • Sequential case number was not significantly associated with increased incidence of complications, surgical blood loss, or positive surgical margins (P= 0.780, P= 0.548, P= 0.545). Case number was, however, significantly associated with shorter operative time and mean number of lymph nodes retrieved (P < 0.001, P < 0.001). • Sequential case number was not significantly associated with survival; however, tumour stage, the presence of lymph node metastases, and positive surgical margins were significantly associated with death. • Although being the largest of its kind, this was a small study with short follow-up when compared to open cystectomy series.
  
  
  CONCLUSIONS
  • Initial experience with RARC did not affect the incidence of positive surgical margins, operative/postoperative complications, or overall survival in a single-institution series.
authors.affiliation: Dept of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA.
authors.forename: Matthew H
authors.initials: MH
authors.lastname: Hayn
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Hellenthal
authors.forename: Stéfanie A
authors.initials: SA
authors.lastname: Seixas-Mikelus
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Mansour
authors.forename: Andrew
authors.initials: A
authors.lastname: Stegemann
authors.forename: Abid
authors.initials: A
authors.lastname: Hussain
authors.forename: Khurshid A
authors.initials: KA
authors.lastname: Guru
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D016063:Blood Loss, Surgical / Q000706:statistics & numerical data; D017024:Chemotherapy, Adjuvant / Q000401:mortality / Q000706:statistics & numerical data; D002983:Clinical Competence / Q000592:standards*; D015653:Cystectomy / Q000401:mortality / Q000592:standards*; D005260:Female; D006801:Humans; D059032:Learning Curve; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000209:etiology / Q000401:mortality; D011446:Prospective Studies; D012307:Risk Factors; D012371:Robotics / Q000592:standards*; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000601:surgery*; D014572:Urology / Q000592:standards* / Q000706:statistics & numerical data